EVAX Stock Forecast 2025-2026
Distance to EVAX Price Targets
EVAX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Evaxion (EVAX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EVAX and similar high-potential opportunities.
Latest EVAX Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, EVAX has a bullish consensus with a median price target of $14.00 (ranging from $6.00 to $19.75). Currently trading at $1.77, the median forecast implies a 691.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Thomas Flaten at Lake Street, suggesting a 239.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVAX Analyst Ratings
EVAX Price Target Range
Latest EVAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Feb 4, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $6.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Sep 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Aug 16, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Aug 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Apr 2, 2024 | Ladenburg Thalmann | Ahu Demir | Buy | Upgrade | $8.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $14.00 |
| Feb 12, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $14.00 |
| Dec 21, 2023 | Ladenburg Thalmann | Ahu Demir | Neutral | Downgrade | $0.00 |
| Mar 31, 2023 | Lake Street | Thomas Flaten | Buy | Maintains | $7.00 |
| Nov 17, 2022 | Oppenheimer | Jeff Jones | Outperform | Maintains | $11.00 |
| Jul 18, 2022 | Oppenheimer | Jeff Jones | Outperform | Assumes | $16.00 |
| Mar 2, 2021 | Oppenheimer | Kevin DeGeeter | Outperform | Initiates | $18.00 |
Evaxion Biotech A/S (EVAX) Competitors
The following stocks are similar to Evaxion based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evaxion Biotech A/S (EVAX) Financial Data
Evaxion Biotech A/S has a market capitalization of $11.18M with a P/E ratio of -0.2x. The company generates $3.30M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +1,859.1% quarter-over-quarter, while maintaining an operating margin of -57.4% and return on equity of +466.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Evaxion Biotech A/S (EVAX) Business Model
About Evaxion Biotech A/S
Develops AI-driven immunotherapies for cancer and diseases.
The company employs proprietary AI platforms to enhance drug discovery, predicting immune responses and identifying target candidates for immunotherapy. This innovative approach allows Evaxion to monetize its research through partnerships, licensing agreements, and potentially by bringing new therapies to market.
Based in Denmark, Evaxion is positioned at the forefront of the biotechnology sector, focusing on precision medicine. Its advancements in AI integration could significantly improve treatment effectiveness and patient outcomes, aligning with the growing trend of AI in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
49
CEO
Country
Denmark
IPO Year
2020
Website
evaxion.aiEvaxion Biotech A/S (EVAX) Latest News & Analysis
Evaxion Biotech (NASDAQ: EVAX) will extend its phase 2 trial of cancer vaccine EVX-01 from two to three years to enhance data collection for advanced melanoma treatment.
Extending the phase 2 trial for EVX-01 indicates a commitment to robust data, potentially increasing the asset's credibility and attractiveness, influencing investor confidence and stock performance.
Evaxion Biotech A/S closed a public offering of 3,997,361 ADSs and warrants, priced at $2.71 per ADS, with one warrant for every two ADSs.
Evaxion's public offering raises capital for its AI-driven vaccine development, potentially enhancing growth prospects. The issuance of warrants indicates investor interest and could affect share dilution.
Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement
1 month agoEvaxion Biotech A/S has received a 180-day extension from Nasdaq to meet stockholder equity requirements, having already restored its equity above the minimum threshold.
Evaxion's compliance with Nasdaq's equity requirement and the extension mitigate delisting risks, potentially stabilizing investor confidence and supporting stock performance.
Evaxion Biotech A/S has priced a public offering of 3,997,361 ADSs and related warrants at $2.71 per ADS, with one warrant for every two ADSs offered.
Evaxion's public offering at $2.71 per ADS and associated warrants could impact share dilution and raise capital for further development, influencing investor sentiment and stock performance.
Evaxion announces completion of ADS ratio change
2 months agoEvaxion Biotech A/S announced the effectiveness of a ratio change for its American Depositary Shares (ADSs) to ordinary shares, DKK 1 nominal value.
The effective change in Evaxion’s ADS ratio can impact share liquidity and trading dynamics, influencing investor sentiment and potentially affecting stock price movements.
Evaxion Biotech A/S will change its ADS ratio from 1 ADS for 10 ordinary shares to 1 ADS for 50 ordinary shares, effective immediately.
The change in ADS ratio affects share liquidity and pricing. A higher ratio can lead to increased share volatility and impact investor sentiment, influencing stock performance.
Frequently Asked Questions About EVAX Stock
What is Evaxion Biotech A/S's (EVAX) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Evaxion Biotech A/S (EVAX) has a median price target of $14.00. The highest price target is $19.75 and the lowest is $6.00.
Is EVAX stock a good investment in 2025?
According to current analyst ratings, EVAX has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVAX stock?
Wall Street analysts predict EVAX stock could reach $14.00 in the next 12 months. This represents a 691.0% increase from the current price of $1.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evaxion Biotech A/S's business model?
The company employs proprietary AI platforms to enhance drug discovery, predicting immune responses and identifying target candidates for immunotherapy. This innovative approach allows Evaxion to monetize its research through partnerships, licensing agreements, and potentially by bringing new therapies to market.
What is the highest forecasted price for EVAX Evaxion Biotech A/S?
The highest price target for EVAX is $19.75 from at , which represents a 1,015.8% increase from the current price of $1.77.
What is the lowest forecasted price for EVAX Evaxion Biotech A/S?
The lowest price target for EVAX is $6.00 from Thomas Flaten at Lake Street, which represents a 239.0% increase from the current price of $1.77.
What is the overall EVAX consensus from analysts for Evaxion Biotech A/S?
The overall analyst consensus for EVAX is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are EVAX stock price projections?
Stock price projections, including those for Evaxion Biotech A/S, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
